BMRN - バイオマリン・ファ―マシュ―ティカルズ (BioMarin Pharmaceutical Inc.) バイオマリン・ファ―マシュ―ティカルズ

 BMRNのチャート


 BMRNの企業情報

symbol BMRN
会社名 BioMarin Pharmaceutical Inc. (バイオマリン・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 バイオマリン・ファーマスーティカル(BioMarin Pharmaceutical Inc.)はバイオテクノロジ企業である。同社はさまざまな病気や病状に対して医薬品の開発と商業化を行う。2016年12月31日現在、同社の治療ポートフォリオは五つの承認医薬品、複数の臨床および前臨床製品候補から構成される。同社の承認医薬品はムコ多糖症I(MPS I)向けのアルデュラザイム(ラロニダーゼ)、ランバートイートン重症筋症(LEMS)向けのファーデサル(リン酸アミンピリジン)、フェニルケトン尿症(PKU)向けのクワン(サプロプテリン二塩酸塩)、ムコ多糖症VI(MPS VI)向けのナガラザイム(ガルスルファイゼ)、ムコ多糖症IV型A(MPS IV A)向けのVimizim (elosulfase alpha)などを含む。同社の臨床候補薬はBrineura、pegvaliase、vosoritide、BMN 270とBMN 250を含む。   バイオマリン・ファ―マシュ―ティカルズは、米国の医薬品メ―カ―。主製品は承認薬5品:ムコ多糖症I治療薬Aldurazyme、ムコ多糖症VI治療薬Naglazyme、フェニルケトン尿症治療薬Kuvan、ランバ―トイ―トン筋無力症候群治療薬Firdapse、ムコ多糖症IV・モルキオ症候群タイプA・リソソ―ム蓄積障害治療薬VIMIZIM。   BioMarin is a global biotechnology company that develops and commercializes innovative therapies for serious and life-threatening rare and ultra-rare genetic diseases. The Company's portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates.
本社所在地 770 Lindaro Street San Rafael CA 94901 USA
代表者氏名 Jean-Jacques Bienaime ジャン=ジャックビエナイム
代表者役職名 Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者
電話番号 +1 415-506-6700
設立年月日 35339
市場名 NASDAQ National Market System
ipoyear 1999年
従業員数 2581人
url www.biomarin.com
nasdaq_url https://www.nasdaq.com/symbol/bmrn
adr_tso
EBITDA EBITDA(百万ドル) -87.42600
終値(lastsale) 101.39
時価総額(marketcap) 18005888222.64
時価総額 時価総額(百万ドル) 18517.35
売上高 売上高(百万ドル) 1438.745
企業価値(EV) 企業価値(EV)(百万ドル) 18345.9
当期純利益 当期純利益(百万ドル) -87.16000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 BioMarin Pharmaceutical Inc. revenues increased 20% to $746.3M. Net loss before extraordinary items increased 23% to $65.5M. Revenues reflect United States segment increase of 29% to $353.4M Europe segment increase of 36% to $178.6M. Higher net loss reflects Research and development - Balancing val increase of 26% to $330.7M (expense) Selling General and Admin - Bal Val increase of 13% to $259.4M (expense).

 BMRNのテクニカル分析


 BMRNのニュース

   Exclusive Research Report On Hemophilia Treatment Market 2021. Major Players CSL Behring, Baxalta, Pfizer Inc, BioMarin, Bayer Healthcare, etc.  2021/07/07 11:30:41 Tramways Monthly
DataIntelo has released their new Hemophilia Treatment Market research report and forecasts for the industry for next eight years. The company predicts that by 2028, there will be a XX% increase in global demand and market will grow with a CAGR of XX%. With this forecast, the future of Hemophilia Treatment market looks bright. The []
   BioMarin resubmits haemophilia A gene therapy to the EMA - PharmaTimes  2021/07/03 16:32:01 The Pharma Times
Company initially withdrew a marketing authorisation application for the gene therapy last year
   BioMarin Announces 12 Presentations at the International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress  2021/07/02 13:05:00 Investors Biomarin
Findings to be Presented from Ongoing Studies of Valoctocogene Roxaparvovec Represent Largest and Longest Development Program for any Gene Therapy in Hemophilia A
   Canada: Plaintiff Cannot Amend Statement Of Claim More Than 45 Days After Receipt Of NOAs To Plead Infringement Of Further Patents - Smart & Biggar  2021/07/02 11:11:38 Mondaq
On May 5, 2021, the Federal Court dismissed a motion by Biomarin Pharmaceutical Inc (Biomarin) to amend its Statement of Claim to allege infringement of two patents that had not been asserted
   Batten Disease Treatment Market (2021-2027) | Latest COVID19 Impact Analysis | Know About Brand Players: Abeona Therapeutics Inc., BioMarin Pharmaceutical Inc., CereSpir Inc., Evotec AG, Ionis Pharmaceuticals Inc., Mitochon Pharmaceuticals Inc., and Spark  2021/07/01 07:51:57 OpenPR
Precision Business Insights published a research report on "Batten Disease Treatment Market by Type of disease (Juvenile NCL (JNCL), Infantile NCL (INCL), Late infant NCL (LINCL), Adult NCL, Others), Treatment (Gene Therapy, Drug Therapy, Enzyme Therapy, Others), Distribution channel (Hospital
   BioMarin''s gene therapy lead jumps ship to rival biotech Vedere Bio II  2021/06/22 12:17:21 FierceBiotech
BioMarin''s gene therapy lead jumps ship to rival biotech Vedere Bio II badams Tue, 06/22/2021 - 08:17
   Is BioMarin Pharmaceutical Inc. (BMRN) A Good Stock To Buy?  2021/06/21 16:17:50 Yahoo Finance
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually dont make them change their opinion towards a company. This time it may be different. The coronavirus pandemic destroyed the high correlations among major industries and asset classes. We are []
   Alzheimer''s Approval Validates Biopharmaceutical Innovation  2021/06/20 10:49:46 Seeking Alpha
   Aurinia Announces Addition of Dr. Brinda Balakrishnan to the Board of Directors  2021/06/14 10:05:00 Business Wire
VICTORIA, British Columbia--(BUSINESS WIRE)---- $AUPH--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) announced today the appointment of Dr. Brinda Balakrishnan, M.D., Ph.D., to the Companys Board of Directors effective June 14, 2021. Dr. Balakrishnan is Group Vice President, Corporate and Business Development of BioMarin Pharmaceutical Inc. (BioMarin), a global biotechnology company that develops and commercializes innovative therapies for patients with serious and li
   Biomarin Pharmaceutical Inc. - Registered Shares (BMRN) gains 4.1770% for June 09 - Equities News  2021/06/14 00:28:18 Equities
Biomarin Pharmaceutical Inc. - Registered Shares (BMRN) gains 4.1770% for June 09 Equities.com
   BioMarin Announces Oral Presentation at ENDO2021, the Endocrine Society's Annual Meeting, with Data Demonstrating 2 Years of Treatment Benefit in Children with Achondroplasia Treated with Vosoritide  2021/03/20 15:15:00 Benzinga
SAN RAFAEL, Calif. , March 20, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that data from the open-label long-term extension of the Phase 3 study of 15 µg/kg dose of vosoritide was presented at an oral presentation at ENDO21, the Endocrine Society's Annual Meeting by Professor Ravi Savarirayan, M.B., B.S., M.D., clinical investigator from the Murdoch Children's Research Institute, Royal Children's Hospital, University of Melbourne , Parkville, Victoria . Vosoritide is an investigational, once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia, the most common form of disproportionate short stature in humans. The data from the open-label extension presented at ENDO21 showed that children maintained an increase in Annual Growth Velocity (AGV) through the second year of continuous treatment with vosoritide. Children who received two years of vosoritide therapy had a baseline mean AGV of 4.28 cm/year. After one year of treatment, mean AGV was 5.71 cm/year and after the second year mean AGV was 5.65 cm/year, demonstrating sustained restoration of a major portion of the growth deficit in achondroplasia through the second year of treatment.
   BIOMARIN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN  2021/03/20 02:50:00 Business Wire
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN). On August 19, 2020, the Company disclosed that it received a Complete Response Letter (“CRL”) from the FDA rejecting its Biologics License Application (“BLA”) for its product, valoctocogene roxaparvovec, and recommending two years of data
   BioMarin Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A  2021/03/08 13:31:00 PR Newswire
SAN RAFAEL, Calif., March 8, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to valoctocogene roxaparvovec, an investigational gene therapy…
   Sebastiani Vineyards names new winemaker  2021/03/05 02:06:00 North Bay Business
Mark Beaman has worked for Sonoma, Mendocino and Washington state vintners. Other news from Fetzer, Visit Napa Valley, BioMarin, To Celebrate Life, West Marin Fund and Vivalon.
   Anthem, BioMarin, CRISPR, GE and More Thursday Afternoon Analyst Calls  2021/03/04 17:25:33 24/7 Wall street

 関連キーワード  (医薬品 米国株 バイオマリン・ファ―マシュ―ティカルズ BMRN BioMarin Pharmaceutical Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)